Intraocular Melanoma Clinical Trial
Official title:
A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor
and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such
as tamoxifen and cisplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Giving sunitinib together with
tamoxifen and cisplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well giving sunitinib
together with tamoxifen and cisplatin works in treating patients with high-risk ocular
melanoma.
OBJECTIVES:
- Determine the effect of adjuvant sunitinib malate, tamoxifen citrate, and cisplatin on
disease-free survival and overall survival of patients with high-risk ocular melanoma
who have undergone primary therapy.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a pilot study.
Patients receive oral sunitinib malate once daily on days 1-21, oral tamoxifen citrate twice
daily on days 1-7, and cisplatin IV on days 2 and 3. Treatment repeats every 28 days for 4
courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 2 months for 2 years.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01217398 -
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 | |
Completed |
NCT00471471 -
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 1 | |
Completed |
NCT00398073 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
N/A | |
Completed |
NCT00334776 -
Vaccine Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00025181 -
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
|
Phase 1 | |
Terminated |
NCT00002947 -
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00897624 -
Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma
|
N/A | |
Completed |
NCT00003339 -
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00084656 -
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00705640 -
Vaccine Therapy in Treating Patients With Advanced Melanoma
|
Phase 1 | |
Completed |
NCT00027742 -
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00952939 -
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
|
N/A | |
Terminated |
NCT00005841 -
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
|
Phase 1 | |
Completed |
NCT00089219 -
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT00072345 -
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00243061 -
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00445965 -
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
|
Phase 2 | |
Terminated |
NCT00110123 -
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
|
Phase 3 | |
Completed |
NCT00032045 -
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00238329 -
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
|
Phase 2 |